| Cancer statistics, 2022. | Ca-A Cancer Journal for Clinicians | 2022 | 842 |
| Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. | Lancet, The | 2022 | 454 |
| Hallmarks of Cancer: New Dimensions. | Cancer Discovery | 2022 | 285 |
| Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. | New England Journal of Medicine | 2022 | 224 |
| Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. | Circulation | 2022 | 196 |
| Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. | Lancet, The | 2022 | 152 |
| Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. | New England Journal of Medicine | 2022 | 124 |
| Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. | Lancet Psychiatry,the | 2022 | 109 |
| Long-term cardiovascular outcomes of COVID-19. | Nature Medicine | 2022 | 108 |
| 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. | Diabetes Care | 2022 | 104 |
| An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. | Nature Medicine | 2022 | 102 |
| A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic in 2020 | Journal of Affective Disorders | 2022 | 100 |
| Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. | Journal of Medical Virology | 2022 | 97 |
| Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. | Lancet Public Health, The | 2022 | 95 |
| 2022 Alzheimer's disease facts and figures. | Alzheimer's and Dementia | 2022 | 95 |
| Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. | JAMA - Journal of the American Medical Association | 2022 | 91 |
| PROTAC targeted protein degraders: the past is prologue. | Nature Reviews Drug Discovery | 2022 | 91 |
| The changing epidemiology of human monkeypox-A potential threat? A systematic review. | PLoS Neglected Tropical Diseases | 2022 | 91 |
| Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | New England Journal of Medicine | 2022 | 88 |
| SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. | New England Journal of Medicine | 2022 | 87 |
| Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. | Lancet, The | 2022 | 86 |
| mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. | Nature Medicine | 2022 | 85 |
| Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. | Lancet, The | 2022 | 82 |
| Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. | JAMA - Journal of the American Medical Association | 2022 | 78 |
| Defining Training and Performance Caliber: A Participant Classification Framework. | International Journal of Sports Physiology and Performance | 2022 | 75 |
